5-Mercury derivatives of 5,6-dihydroprostacyclin compounds

ABSTRACT

Mercury derivatives of 5,6-dihydroprostacyclins are disclosed, illustrated for example by ##STR1## wherein G is nitrato, iodo, chloro, bromo, acetato, trifluoroacetato, or benzoato, and wherein ˜ indicates alpha or beta configuration, said products having pharmacological activity.

CROSS REFERENCE TO RELATED APPLLICATIONS

This is a division, of application Ser. No. 857,236, filed Dec. 5, 1977 now U.S. Pat. No. 4,125,712, which is a continuation-in-part of copending application Ser. No. 788,146 filed Apr 19, 1977, now abandoned which was a continuation-in-part of then copending applicaton Ser. No. 691,400 filed June 1, 1976 now abandoned.

BACKGROUND OF THE INVENTION

This invention relates to products having prostacyclin-like structure and to processes for preparing them. In particular this invention relates to 5-mercury derivatives of 5,6-dihydroprostacyclin compounds and to processes for preparing them.

The essential material for this application, including the background of the invention, the disclosure of the invention, and the description of the preferred embodiments, including Prepartions and Examples, is incorporated by reference from commonly owned U.S. Pat. No. 4,125,712, especially columns 33-34, 52-54, and 84-105, under the proviso of M.P.E.P. 608.01(p).

SUMMARY OF THE INVENTION

It is the purpose of this invention to provide novel products having pharmacological activity and utility as intermediates. It is a further purpose to provide processes for preparing these products and their intermediates.

The terms L, Q₂, etc. as used hereinafter are as defined in the Table of Definitions herein.

TABLE Definition of Terms for Formulas

G is nitrato, iodo, chloro, bromo, acetato, trifluoroacetato, or benzoato.

L is (1) a valence bond, (2) --(CH₂)_(d) --wherein d is one to 5 inclusive, (3) --(CH₂)_(t) --CF₂ --wherein t is 2, 3, or 4, (4)--CH₂ --CH═CH--A--wherein A is a valence bond or --(CH₂)_(h) --wherein h is one, 2, or 3, or (5) --CH₂ --O--CH₂ --Y--wherein Y is a valence bond or --(CH₂)_(k) --wherein k is one or 2.

Q₂ is ##STR2## wherein R₃ is hydrogen or alkyl of one to 4 carbon atoms, inclusive, and wherein R₄ is hydrogen, tetrahydropyran-2-yl, tetrahydrofuranyl, 1-ethoxyethyl or a group of the formula ##STR3## wherein R₈ is alkyl of one to 18 carbon atoms, inclusive, cycloalkyl of 3 to 10 carbon atoms, inclusive, aralkyl of 7 to 12 carbon atoms, inclusive, aralkyl of 7 to 12 carbon atoms, inclusive, phenyl, or phenyl substituted with one, 2, or 3 alkyl of one to 4 carbon atoms, inclusive, wherein R₉ and R₁₀ are the same or different, being hydrogen, alkyl of one to 4 carbon atoms, inclusive, phenyl or phenyl substituted with one, 2, or 3 alkyl of one to 4 carbon atoms, inclusive, or, when R₉ and R₁₀ are taken together, --(CH₂)_(a) --or --(CH₂)_(b) --O--(CH₂)_(c) --wherein "a" is 3, 4, or 5, b is one, 2, or 3, and c is one, 2, or 3 with the proviso that b plus c is 2, 3, or 4, and wherein R₁₁ is hydrogen or phenyl.

R₃ and R₄ are as defined above for Q₂.

is ##STR4## wherein R₄ is as defined above for Q₂. R₂₅ is

(1) ##STR5## wherein C_(g) H₂.sbsb.g is alkylene of one to 9 carbon atoms, inclusive, with one to 5 carbon atoms, inclusive, in the chain between --CR₅ R₆ --and terminal methyl, wherein R₅ and R₆ ar hydrogen, alkyl of one to 4 carbon atoms, inclusive, or fluoro, being the same or different, with the proviso that one of R₅ and R₆ is fluoro only when the other is hydrogen or fluoro;

(2) ##STR6## wherein R₅ and R₆ are as defined above with the proviso that neither R₅ nor R₆ is fluoro when Z is oza (--O--); wherein Z represents an oxa atom (--0--) or C_(j) H₂.sbsb.j wherein C_(j) H₂.sbsb.j is a valence bond or alkylene of one to 9 carbon atoms, inclusive, with one to 6 carbon atoms, inclusive between --CR₅ R₆ --and the phenyl ring; wherein T is alkyl of one to 4 carbon atoms, inclusive, fluoro, chloro, trifluoromethyl, or --OR₇ --wherein R₇ is alkyl of one to 4 carbon atoms, inclusive, and s is zero, one, 2, or 3, with the proviso that not more than two T's are other than alkyl and when s is 2 or 3 the T's are either the same or different; or

(3) ##STR7## R₃₀ is (1) --COOR₁₉

(2) --ch₂ oh

(3)--ch₂ n(r₁₈)₂

(4) ##STR8## (5) ##STR9## wherein R₁₉ is (a) alkyl of one to 12 carbon atoms, inclusive,

(b) cycloalkyl of 3 to 10 carbon atoms, inclusive,

(c) aralkyl of 7 to 2 carbon atoms, inclusive,

(d) phenyl.

(e) phenyl substituted with one, 2, or 3 chloro or alkyl of one to 4 carbon atoms, inclusive, ##STR10## wherein R₃₄ is phenyl, p-bromophenyl, p-biphenylyl, p-nitrophenyl, p-benzamidophenyl, or 2-naphthyl, and wherein R₃₅ is hydrogen or benzoyl,

(m) hydrogen; or

(n) a pharmacologically acceptable cation; and wherein R₁₈ is hydrogen, alkyl of one to 12 carbon atoms, inclusive, benzyl, or phenyl, being the same or different.

R₃₆ is the same as R₃₀ except that it does not include salts in which R₁₉ of --COOR₁₉ is a pharmacologically acceptable cation.

X is trans--CH═CH--, cis--CH═CH--, --C.tbd.C--, or --CH₂ CH₂ --.

The symbol ˜ (wavy line) indicates attachment in alpha or beta configuration.

Accordingly there are provided mercury compounds of the formula ##STR11##

wherein G is nitrato, iodo, chloro, bromo, acetato, trifluoroacetato, or benzoato;

and wherein L, Q₂, , R₂₅ , R₃₀, X, and ˜ are as defined above.

There are also provided mercury compounds of the formula ##STR12## wherein L, Q₂, , R₂₅, X, and ˜ are as defined above.

The novel mercury compounds disclosed herein are useful for pharmacological purposes. They have antiprotozoal and antisyphilitic activity and are consequently effective in treating streptococci and staphylococci. They have antimicrobial activity and are useful for topical antiseptic treatment for animals, including humans, useful domestic animals, pets, zoological specimens, and laboratory animals. They are further useful in ophthalmiatrics.

For these purposes, these mercury compounds are preferably administered topically, for example in alcoholic solution at 0.002 to 0.01% concentration with a benzalkonium chloride as a preservative, or as a lotion, cream, or ointment in 0.5-5.0% concentration in combination with the usual pharmaceutically acceptable diluents. The exact application and concentration depends on such factors as the age, weight and condition of the subject.

Certain mercury compounds within the scope of formula XXXV are preferred for optimum biological response specificity, potency, and duration of activity. For example it is preferred that Q₂ be ##STR13## wherein R₄ is hydrogen; it is further preferred that L be trimethylene. When R₃ is alkyl, it is preferred that R₃ be methyl. Likewise, as to R₃₀, when R₁₉ in -COOR₁₉ is alkyl, it is preferred that R₁₉ be alkyl of one to 4 carbon atoms, especially methyl. Another preference is that G be chloro or acetato. 

I claim:
 1. A mercury compound of the formula ##STR14## wherein G is nitrato, iodo, chloro, bromo, acetato, trifluoracetato, or benzoato;wherein L is (1) a valence bond, (2) --(CH₂)_(d) --wherein d is one to 5 inclusive, (3) --(CH₂)_(t) --CF₂ wherein t is 2, 3, or 4, (4) --CH₂ --CH═CH--A-- wherein A is a valence bond or --(CH₂)_(h) --wherein h is one, 2, or 3, or (5) --CH₂ --O--CH₂ --Y--wherein Y is a valence bond or --(CH₂)_(k) --wherein k is one or 2; wherein Q₂ is ##STR15## wherein R₃ is hydrogen or alkyl of one to 4 carbon atoms, inclusive, and wherein R₄ is hydrogen, tetrahydropyranyl, tetrahydrofuranyl, 1-ethoxyethyl or a group of the formula ##STR16## wherein R₈ is alkyl of one to 18 carbon atoms, inclusive, cycloalkyl of 3 to 10 carbon atoms, inclusive, aralkyl of 7 to 12 carbon atoms, inclusive, phenyl, or phenyl substituted with one, 2, or 3 alkyl of one to 4 carbon atoms, inclusive, wherein R₉ and R₁₀ are taken together, --(CH₂)_(a) --or --(CH₂)_(b) --O--(CH₂)_(c) --wherein a is 3, 4, or 5, b is one, 2, or 3, and c is one, 2, or 3 with the proviso that b plus c is 2, 3, or 4, and wherein R₁₁ is hydrogen or phenyl; wherein R₂₂ is ##STR17## wherein R₄ is as defined above; wherein R₂₅ is(1) ##STR18## wherein C_(g) H₂.sbsb.g is alkylene of one to 9 carbon atoms, inclusive, with one to 5 carbon atoms, inclusive in the chain between --CR₅ R₆ --and terminal methyl, wherein R₅ and R₆ are hydrogen, alkyl of one to 4 carbon atoms, inclusive, or fluoro, being the same or different, with the proviso that one of R₅ and R₆ is fluoro only when the other is hydrogen or fluoro; (2) ##STR19## wherein R₅ and R₆ are as defined above with the proviso that neither R₅ nor R₆ is fluoro when Z is oxa (--O--); wherein Z represents an oxa atom (--O--) or C_(j) H_(2j) wherein C_(j) H_(2j) is a valence bond or alkylene of one to 9 carbon atoms, inclusive, substituted with zero, one, or 2 fluoro, with one to 6 carbon atoms, inclusive between --CR₅ R₆ --and the phenyl ring; wherein T is alkyl of one to 4 carbon atoms, inclusive, fluoro, chloro, trifluoromethyl, or --OR₇ wherein R₇ is alkyl of one to 4 carbon atoms, inclusive, and s is zero, one, 2, or 3, with the proviso that not more than two T's are other than alkyl and when s is 2 or 3 the T's are either the same or different; or (3) ##STR20## wherein R₃₀ is (1) -COOR₁₉ (2) -ch₂ oh (3) -ch₂ n(r₁₈)₂ ##STR21## wherein R₁₉ is (a) alkyl of one to 12 carbon atoms, inclusive,(b) cycloalkyl of 3 to 10 carbon atoms, inclusive, (c) aralkyl of 7 to 12 carbon atoms, inclusive, (d) phenyl, (e) phenyl substituted with one, 2, or 3 chloro or alkyl of one to 4 carbon atoms, inclusive; ##STR22## wherein R₃₄ is phenyl, p-bromophenyl, p-biphenylyl, p-nitrophenyl, p-benzamidophenyl, or 2-naphthyl, and wherein R₃₅ is hydrogen or benzoyl, (m) hydrogen, or (n) a pharmacologically acceptable cation; and wherein R₁₈ is hydrogen, alkyl of one to 12 carbon atoms, inclusive, benzyl, or phenyl, being the same or different; wherein X is trans--CH═CH--, cis--CH═CH--, --C.tbd.C--, or --CH₂ CH₂ --; and wherein ˜ indicates attachment in alpha or beta configuration.
 2. 5-Chloromercurio-9-deoxy-6ξ,9α-epoxy-PGF₁, methyl ester, compounds according to claim
 1. 3. A mercury compound of the formula ##STR23## wherein L is --(CH₂)_(d) --or --CH₂ O--CH₂ --Y-- wherein d is one to 5, inclusive, and Y is a valence bond or --(CH₂)_(k) -- where k is one or 2; wherein R₂ is(1) ##STR24## wherein C_(g) H₂.sbsb.g is alkylene of one to 9 carbon atoms, inclusive, with one to 5 carbon atoms, inclusive, in the chain between --CR₅ R₆ -- and terminal methyl, wherein R₅ and R₆ are hydrogen, alkyl of one to 4 carbon atoms, inclusive, or fluoro, being the same or different, with the proviso that one of R₅ and R₆ is fluoro only when the other is hydrogen or fluoro; or (2) ##STR25## wherein R₅ and R₆ are as defined above with the proviso that neither R₅ nor R₆ is fluoro when Z is oxa (--O--); wherein Z represents an oxa atom (--O--) or C_(j) H_(2j) wherein C_(j) H_(2j) is a valence bond or alkylene of one to 9 carbon atoms, inclusive, with one to 6 carbon atoms, inclusive between --CR₅ R₆ -- and the phenyl ring; wherein T is alkyl of one to 4 carbon atoms, inclusive, fluoro, chloro, trifluoromethyl, or --OR₇ wherein R₇ is hydrogen or alkyl of one to 4 carbon atoms, inclusive, and s is zero, one, 2, or 3, with the proviso that not more than two T's are other than alkyl and when s is 2 or 3 the T's are either the same or different; wherein Q₃ is ##STR26## wherein R₃ is hydrogen or alkyl of one to 4 carbon atoms, inclusive; and wherein ˜ indicates attachment in alpha or beta configuration.
 4. 5-Chloromercurio-9-deoxy-6ξ,9α-epoxy-PGF₁, methyl ester, less polar isomer, a compound according to claim
 2. 5. 5-Chloromercurio-9-deoxy-6ξ,9α-epoxy-PGF₁, methyl ester, more polar isomer, a compound according to claim
 2. 6. 5-Chloromercurio-9-deoxy-6ξ,9α-epoxy-17-phenyl-18,19,20-trinor-PGF₁, methyl ester, compounds according to claim
 1. 7. 5-Chloromercurio-9-deoxy-6ξ,9α-epoxy-16,16-dimethyl-PGF₁, methyl ester, compounds according to claim
 1. 8. 5-Chloromercurio-9-deoxy-6ξ,9α-epoxy-16-phenoxy-17,18,19,20-tetranor-PGF₁, compounds according to claim
 1. 9. 5-Chloromercurio-9-deoxy-6ξ,9α-epoxy-PGF₁, compounds according to claim
 1. 10. 5-Acetatomercurio-9-deoxy-6ξ, 9α-epoxy-PGF₁, methyl ester, compounds according to claim
 1. 